Enanta Pharmaceuticals, Inc.
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identifyā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$12.60
Price-3.08%
-$0.40
1Y
Price
Market Cap
$366.388m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-107.6%
EBITDA Margin-123.6%
Net Profit Margin+114.7%
Free Cash Flow Margin-107.6%
EBITDA Margin-123.6%
Net Profit Margin+114.7%
Free Cash Flow MarginRevenue
$69.213m
-3.4%
1y CAGR-8.7%
3y CAGR-9.3%
5y CAGREarnings
-$61.984m
+29.4%
1y CAGR+10.9%
3y CAGR-5.3%
5y CAGREPS
-$2.74
+30.1%
1y CAGR+12.1%
3y CAGR-3.6%
5y CAGRBook Value
$116.587m
$314.704m
Assets$198.117m
Liabilities$186.617m
DebtDebt to Assets
59.3%
-2.8x
Debt to EBITDAFree Cash Flow
-$9.609m
+55.0%
1y CAGR+13.2%
3y CAGR+4.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company